Evaluation of the synergistic effect of Curcuma aromatica in combination with sorafenib on a hepatoblastoma cell line In vitro

Liver cancer is one of the most common cancers, accounting for the sixth-highest number of new cases and the third-highest number of deaths. Sorafenib is a well-known targeted therapy for the treatment of liver cancer. Sorafenib's therapeutic use has also been linked to side effects such as diarrhea, hypertension, and skin toxicity. As a result, combining Sorafenib with other therapeutic agents is required to avoid unwanted side effects. In this study, we tried to test the combination effect of Sorafenib and Curcuma aromatica extract. The cytotoxic, migration, and colony assays were used to investigate the conjugated effect of C. aromatica extract and Sorafenib on liver cancer cell growth inhibition. At the same Sorafenib concentration, the more C. aromatica extract supplemented, the higher the cell death rate, with a statistically significant difference. To assess the relative potency of the combination, an isobologram model integrated into the CalcuSyn software was used. All of the data points were located in a synergistic area below the additive line, according to the schematic isobologram and CI distribution chart. The results indicated that the effect of sorafenib and C. aromatica was synergistic. C. aromatica extract could be used to help treat liver cancer when used with sorafenib.